Moderna Outlines Commitment to Corporate Growth and Announces U.S. Expansion in 2023

Posted: 15 March 2023

Moderna, a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that it is expanding its U.S. presence and establishing a corporate presence on the West Coast with new offices in South San Francisco, California and Seattle, Washington. Moderna’s Seattle location will provide technology solutions across the enterprise and Moderna Genomics will expand to South San Francisco. Moderna also plans to hire approximately 2,000 new employees globally by the end of 2023.

Moderna’s West Coast presence joins additional U.S. locations in Cambridge, Massachusetts; Norwood, Massachusetts; Atlanta, Georgia; Bethesda, Maryland; and Princeton, New Jersey.

“Our team has continued to push beyond what we ever imagined possible to completely reimagine how medicines are created and delivered. We are making significant investments in both people and infrastructure to build the most impactful version of Moderna,” said Tracey Franklin, Chief Human Resources Officer of Moderna. “At Moderna, we give our people a platform to change medicine and an opportunity to change the world.”

Moderna’s new office in Seattle will provide technology solutions across the enterprise and further scale the implementation of artificial intelligence (AI) and cloud-based tools across the platform by capitalizing on the region’s existing technology talent. The Company is hiring Technical Program Managers, Product Managers and Software Development Engineers. To learn more and apply for open roles, click here.

“Moderna is investing to fully realize our ambition of embedding technology into everything we do. By building technology solutions that enable business, scientific and people-led breakthroughs, we will continue to make a positive impact on the people we serve,” said Brad Miller, Chief Information Officer of Moderna. “We are hiring rapidly in-market across key tech capabilities and are excited to grow our presence in Seattle, an area rich in highly skilled talent.”

This U.S. expansion comes as Moderna is rapidly advancing its pipeline of mRNA medicines, including mRNA-4157, the Company’s personalized cancer vaccine candidate, being developed in collaboration with Merck, which was recently granted Breakthrough Therapy Designation by the U.S. FDA, as well as mRNA-1345, the Company’s RSV vaccine candidate, which was also recently granted Breakthrough Therapy Designation by the U.S. FDA based on positive topline data from the ConquerRSV Phase 3 pivotal efficacy trial.

Moderna currently has 48 mRNA programs1 in development of which 38 are in active clinical trials. Currently, the Company currently has operations in 17 countries worldwide.

Moderna was recognized as a top employer in 2022 for the eighth consecutive year in a row by Science and Science Careers, and was ranked the number one large employer in BioSpace’s 2023 Best Places to Work in Biopharma report.

Find out more.


News & opinion

Member Directory